Key result
Compact PpCas9 cleaves DNA in human cells and requires an NNNNRTT PAM orthogonal to SpCas9.
Why the study?
The large size and PAM sequence restrictions of SpCas9 limit its genome editing applications, and few Type II-C Cas9 orthologs have been fully characterized.
PpCas9 is a compact Type II-C Cas9 ortholog active in human cells with a novel PAM requirement, potentially broadening CRISPR-Cas9 applications.
CRISPR-Cas defense systems opened up the field of genome editing due to the ease with which effector Cas nucleases can be programmed with guide RNAs to access desirable genomic sites. Type II-A SpCas9 from Streptococcus pyogenes was the first Cas9 nuclease used for genome editing and it remains the most popular enzyme of its class. Nevertheless, SpCas9 has some drawbacks including a relatively large size and restriction to targets flanked by an 'NGG' PAM sequence. The more compact Type II-C Cas9 orthologs can help to overcome the size limitation of SpCas9. Yet, only a few Type II-C nucleases were fully characterized to date. Here, we characterized two Cas9 II-C orthologs, DfCas9 from Defluviimonas sp.20V17 and PpCas9 from Pasteurella pneumotropica. Both DfCas9 and PpCas9 cleave DNA in vitro and have novel PAM requirements. Unlike DfCas9, the PpCas9 nuclease is active in human cells. This small nuclease requires an 'NNNNRTT' PAM orthogonal to that of SpCas9 and thus potentially can broaden the range of Cas9 applications in biomedicine and biotechnology.
No takes yet. Share an insight, caveat, or question.
Fedorova et al. (2020) studied this question. PpCas9 and DfCas9 vs. SpCas9 was evaluated on DNA cleavage in vitro and activity in human cells. PpCas9 is a compact Type II-C Cas9 ortholog that cleaves DNA in vitro, is active in human cells, and requires an 'NNNNRTT' PAM orthogonal to that of SpCas9.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: